Skip to main content

Table 6 Relative healthcare cost per month by baseline iPTH, total calcium, and phosphate in sensitivity analyses

From: Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study

Baseline level*

Follow-up duration 3 months (N=5009)

Follow-up duration 6 months (N=4370)

Total healthcare cost > €0 (N=4938)

n

Relative Cost(95% CI)

n

Relative Cost(95% CI)

n

Relative Cost†‡(95% CI)

iPTH, pg/mL

  < 75

965

0.90 (0.81, 1.00)

837

0.81 (0.72, 0.90)

937

1.00 (0.91, 1.10)

  ≥ 75 – < 150

1064

1.02 (0.92, 1.13)

928

1.00 (0.90, 1.11)

1052

0.99 (0.91, 1.09)

  ≥ 150 – ≤ 300 (reference)

1295

1.00

1124

1.00

1284

1.00

  > 300 – ≤ 600

1068

1.14 (1.03, 1.27)

926

1.05 (0.95, 1.17)

1060

1.10 (1.00, 1.20)

  > 600

617

1.50 (1.32, 1.70)

555

1.37 (1.20, 1.56)

605

1.40 (1.25, 1.57)

Total calcium (mmol/L)

  < 2.10 mmol/L

766

0.96 (0.87, 1.07)

631

0.95 (0.85, 1.06)

759

1.01 (0.92, 1.11)

  ≥ 2.10 – ≤ 2.37 mmol/L (reference)

2773

1.00

2397

1.00

2742

1.00

  > 2.37 mmol/L

1311

1.03 (0.94, 1.12)

1195

1.00 (0.92, 1.10)

1274

1.10 (1.02, 1.19)

  Missing

159

1.41 (1.02, 1.96)

147

1.14 (0.82, 1.58)

163

1.52 (1.18, 1.95)

Phosphate (mmol/L)

      

  < 1.13 mmol/L

764

0.77 (0.70, 0.86)

673

0.80 (0.71, 0.89)

732

0.78 (0.71, 0.85)

  ≥ 1.13 – ≤ 1.78 mmol/L (reference)

2889

1.00

2526

1.00

2856

1.00

  > 1.78 mmol/L

1131

1.37 (1.25, 1.50)

960

1.44 (1.31, 1.58)

1116

1.38 (1.27, 1.50)

  Missing

225

0.87 (0.64, 1.16)

211

0.85 (0.63, 1.15)

234

0.73 (0.59, 0.92)

  1. iPTH, intact parathyroid hormone.
  2. *Mean during 3-month baseline period.
  3. Based on pooled data for Hungary, Italy, Portugal, Spain, and Turkey, adjusted for iPTH, total calcium, phosphate, duration of follow-up, age, sex, chronic kidney disease aetiology, history of cardiovascular disease, diabetes and cancer, dialysis vintage, C-reactive protein, albumin, haemoglobin, ferritin, total cholesterol and blood leukocyte count.
  4. Only the second-part results of the two-part model are presented.